RESEARCH ARTICLE

Atopic biomarker changes after exposure to *Porphyromonas gingivalis* lipopolysaccharide: a small experimental study in Wistar rats [version 1; peer review: awaiting peer review]

Sindy Cornelia Nelwan¹, Ricardo Adrian Nugraha², Anang Endaryanto³, Asti Meizarini⁴, Udijanto Tedjosasongko¹, Seno Pradopo¹, Haryono Utomo⁵, Nunthawan Nowwarote⁶

¹Department of Pediatric Dentistry, Universitas Airlangga, Surabaya, Jawa Timur, 60235, Indonesia
²Department of Cardiology and Vascular Medicine, Universitas Airlangga, Surabaya, Jawa Timur, 60235, Indonesia
³Division of Pediatric Allergy and Immunology, Department of Child Health, Universitas Airlangga, Surabaya, Jawa Timur, 60235, Indonesia
⁴Department of Dental Materials, Science and Technology, Universitas Airlangga, Surabaya, Jawa Timur, 60235, Indonesia
⁵Department of Forensic Odontology, Universitas Airlangga, Surabaya, Jawa Timur, 60235, Indonesia
⁶Centre de Recherche des Cordeliers, INSERM UMRS 1138, Molecular Oral Pathophysiology, Université de Paris, Sorbonne Université, Paris, 75006, France

First published: 11 May 2021, 10:371
https://doi.org/10.12688/f1000research.51959.1

Abstract

**Background:** IgE and IgG₄ are implicated in atopic development and clinically utilized as major biomarkers. Atopic responses following certain pathogens, such as *Porphyromonas gingivalis* (Pg), are currently an area of interest for further research. The aim of this study is to measure the level of IgE, IgG₄, and IgG₄/IgE ratio periodically after exposure of periodontal pathogen Pg lipopolysaccharide (LPS).

**Methods:** We used 16 Wistar rats (*Rattus norvegicus*) randomly subdivided into four groups: Group 1, injected with placebo; Group 2, injected with LPS Pg 0.3 µg/mL; Group 3, injected with LPS Pg 1 µg/mL; and Group 4, injected with LPS Pg 3 µg/mL. Sera from all groups were taken from retro-orbital plexus before and after exposure.

**Results:** Levels of IgE and IgG₄ increased significantly following exposure of LPS Pg at day-4 and day-11. Greater increase of IgE rather than IgG₄ contributed to rapid decline of IgG₄/IgE ratio, detected in the peripheral blood at day-4 and day-11.

**Conclusion:** Modulation of atopic responses following exposure to LPS Pg is reflected by a decrease in IgG₄/IgE ratio that accompanies an increase of IgE. Therefore, Pg, a keystone pathogen during periodontal disease, may have a tendency to disrupt atopic biomarkers.
Keywords
allergic diseases, atopic inflammatory pathway, immunoglobulin, periodontal pathogen, Porphyromonas gingivalis LPS

Corresponding author: Sindy Cornelia Nelwan (sindy-c-n@fkg.unair.ac.id)

Author roles: Nelwan SC: Conceptualization, Data Curation, Formal Analysis, Funding Acquisition, Project Administration; Nugraha RA: Data Curation, Formal Analysis, Investigation, Methodology, Writing – Original Draft Preparation; Endaryanto A: Resources, Software, Supervision, Validation, Writing – Review & Editing; Meizarini A: Resources, Software, Visualization; Tedjosasonko U: Supervision, Writing – Review & Editing; Pradopo S: Supervision, Writing – Review & Editing; Utomo H: Funding Acquisition, Supervision, Visualization, Writing – Review & Editing; Nowwarote N: Supervision, Writing – Review & Editing

Competing interests: No competing interests were disclosed.

Grant information: The author(s) declared that no grants were involved in supporting this work.

Copyright: © 2021 Nelwan SC et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Nelwan SC, Nugraha RA, Endaryanto A et al. Atopic biomarker changes after exposure to Porphyromonas gingivalis lipopolysaccharide: a small experimental study in Wistar rats [version 1; peer review: awaiting peer review]
F1000Research 2021, 10:371 https://doi.org/10.12688/f1000research.51959.1
First published: 11 May 2021, 10:371 https://doi.org/10.12688/f1000research.51959.1
Introduction
The oral cavity is the habitat of numerous bacteria, including Porphyromonas gingivalis (Pg). Pg is a gram negative, facultative anaerobic pathogen, which is responsible in causing gingivitis or periodontitis.1 In low-income countries, gingivitis and periodontitis can affect up to 90% of the adult population.2 Rather than alveolar bone and ligament destruction, Pg is believed to be involved with the development of atopic responses in a susceptible host.3 Following Pg infection, hosts’ adaptive immune response (both cell-mediated and humoral-mediated) could induce a systemic inflammatory reaction, not only just local destruction of tooth-supporting tissues.4,5 Although periodontal pathogens, such as Pg, play a major role in the initiation of local and systemic inflammatory reaction,6 the host aberrant immune responses require further study. Since humoral immune responses are stimulated following Pg infection, there might be a link to the occurrence of atopy.

Despite long-standing research about hygiene hypothesis for several decades, there is an unequivocally accepted fact that the prevalence of atopy increases more among children who have periodontal pathogen colonization or infection.7 While endorsing these hygiene hypothesis approaches, there is an alternative hypothesis in which exposure to some periodontal pathogens will exclusively trigger an “immunoglobulin-E skew” rather than reducing it.8 Within the context of the hygiene hypothesis, the most essential microbial exposures needed to be studied is the biomolecular relationship between host antibody and regulatory T-cell with lipopolysaccharide (LPS), an endotoxin released by Pg to affect host immune reaction.

Hygiene hypothesis principles might not be able to answer all phenomenon of increasing incidence of atopy among children with poor oral hygiene.9 Some studies report a positive association between the colonization/infection of Pg with the development of allergic diseases,10–15 whereas some studies report no association.16–21 Due to lack of conclusive evidence about the association between Pg and allergic diseases,22 we try to measure the level of atopic biomarkers following Pg infection.

To the best of our knowledge, measuring IgG4 and IgE antibody may have a closer association to atopic profiles, since IgG4 and IgE are released after activation of mature B cells following the modulation of IL-4 and IL-5 released by Th-2 cells during type I hypersensitivity.23 By looking at the alteration of IgG4 and IgE antibodies level after exposure to these selected components of Pg in a rat model, we hope to understand more deeply the biological mechanism of B-cell production antibodies pattern and humoral immune responses before the clinical manifestation of atopy. We chose a rat model since they are inbred so they are almost identical genetically and their genetic, biological and behavior characteristics closely resemble those of humans.

Methods
Ethics approval
This article was reported in line with the ARRIVE guidelines. Animal experimental study was conducted under the approval of the Institutional Animal Research Ethics Committee of Universitas Airlangga (UNAIR), Surabaya, Indonesia (animal approval no:50/KKEPK.FKG/IV/2015) under the name of Sindy Cornelia Nelwan as the Principal Investigator. The study was carried out in strict accordance to internationally accepted standards of the Guide for the Care and Use of Laboratory Animals of the National Institute of Health. All efforts were made to ameliorate any suffering of animals through using anaesthetic to euthanize the rats at the end of the experimental procedure.

Animals
Sample size

\[ N = \left( \frac{Z_{\alpha/2}}{2}\right)^2 \frac{s^2}{d^2}, \]

where \( s \) is the standard deviation obtained from previous study or pilot study, and \( d \) is the accuracy of estimate or how close to the true mean. \( Z_{\alpha/2} \) is normal deviate for two-tailed alternative hypothesis at a level of significance. Suppose sample size calculated by software is 3 animals per group and researcher is expecting 10% attrition then his final sample size will be 4 animals per group or 16 animals in total.

Rats

The present study used 16 male Wistar rats (Rattus norvegicus) between eight and ten weeks of age (average body weight 120-150 grams). The rats were housed in microisolator cages and maintained in a constant room temperature ranging from 22°C to 25°C, with a 12-h light/12-h dark cycle, under artificially controlled ventilation, with a relative humidity ranging from 50% to 60%. The rats were fed a standard balanced rodent diet (NUTRILAB CR-1®) and water were provided ad libitum.
Inclusion criteria was male Wistar rats, age 8-10 weeks, with body weight 120-150 grams. Female Wistar rats, diseased, sick, and lazy male Wistar rats were strictly excluded.

Experimental design and groups
The present study design was a pre-test post-test-controlled unblinded group design using quantitative method. The 16 male Wistar rats were randomized using randomized block sampling and classified into four groups. Each group consisted of 4 matched Wistar rats (age, weight, IgE and IgG baseline characteristic). Group 1 were given placebo (0.9% normal saline solution). Group 2 were given lipopolysaccharide (LPS) of Porphyromonas gingivalis (Pg) (American Type Culture Collection, Rockville, Md.) at dose 0.3 μg/mL. Group 3 were given LPS Pg at dose 1 μg/mL. Group 4 were given LPS Pg at dose 3 μg/mL.

The rats received LPS by an intra-sulcular injection. Intra-sulcular injection has an advantage due to the its direct delivery of LPS to oral cavity in which the tip of needle is injected slowly at the crestal bone. Longitudinal quantitative measurement was performed: IgE level, IgG4 level, and IgG4/IgE ratio in both groups on day-0 (before treatment), day-4, and day-11. An average of 0.2 ml peripheral blood sera was obtained by Pasteur pipette from retro-orbital plexus, using a lateral approach on each of these days from each rat. The potential expected adverse events were anaphylactic shock, allergic reaction, bleeding and infection. However, to the best our knowledge, there were no expected nor unexpected adverse events in the experimental procedures. Following the end of the experiments, all efforts were made to ameliorate any suffering of animals through injection of sodium pentobarbital anesthetic to euthanize the rats at the end of the experimental procedure.

Level of IgG4 and IgE
Sample of the sera were collected and stored at −70°C (−94°F) at Institute of Tropical Diseases Universitas Airlangga (UNAIR). All sera were assessed by direct-sandwich enzyme-linked immunosorbent assay (ELISA) with mouse IgE antibody (MAB9935) and IgG4 antibody (MAB9895) under the manufacturer’s (R&D System Europe Ltd, Abingdon, UK) protocol. Briefly, the sera were examined using microtiter plates using 25 ml of 3,3',5,5'-tetramethylbenzidine to 1 ml of phosphate-citrate buffer plus perborate in a mildly acidic buffer (adjust pH 5.7). Levels of IgG4 were detected using monoclonal antibody anti-IgG4, transferring it to microtiter plates, adding the supplied conjugate, adding blocking solution, diluting plasma sample (1:100,000), and washing between the steps. Level of IgE was detected using monoclonal antibody anti-IgE, following similar steps until diluting the plasma sample (1:200). A minimum value of 0.01 pg/mL for IgE and 0.01 ng/mL for IgG4 were assigned for below the limit of detection. We used 3,3',5,5'-tetramethylbenzidine as chromogenic substrate, which allows direct visualization of signal development through spectrophotometer.

Statistical analysis
All measurements were performed at least three times. Results were presented as means ± standard errors (SEM). The assumption of the normality for the complete data was assessed by Shapiro-Wilk test. Test of homogeneity of variances was assessed by Levene Statistics. Statistical significance was examined by one-way ANOVA and repeated measure ANOVA using SPSS version 17.0 for Microsoft (IBM corp, Chicago, USA).

Results
General characteristic investigations
Table 1 show the baseline characteristics of the 16 Wistar rats (Rattus norvegicus). No significant differences were found for mean age (p = 0.774), body weight (p = 0.700), baseline IgE (p = 0.071), baseline IgG4 (p = 0.770), and baseline IgG4/ IgE ratio (p = 0.053) among the four groups.

Comparison of serum IgE level between the four groups
Prior to experiments (day-0), there was no difference of serum IgE level between the four groups (p > 0.05). On day-4, there was a significance difference of serum IgE level between all groups (p = 0.006). At day-4, the highest average IgE level could be found in Group 3 treated with LPS Pg 1 μg/ml (17.00 ± 1.69 pg/ml) and the lowest average IgE level could be found in Group 1 (control) (5.31 ± 0.76 pg/ml). On day-11, there was also a significance difference of serum IgE level between both groups (p = 0.047). At day-11 the highest average IgE level could be found in Group 2 treated with LPS Pg 0.3 μg/ml (180.34 ± 10.42 pg/ml) and the lowest average IgE level could be found in Group 1 (5.06 ± 1.86 pg/ml) (Table 2).

Comparison of serum IgG4 level between the four groups
Prior to experiments (day-0), there was no difference of serum IgG4 level between the four groups (p > 0.05). On day-4, there was a significance difference of serum IgG4 level between all groups (p = 0.008). At day-4, the highest average IgG4 level could be found in Group 4 (LPS Pg 3 μg/ml; 23.86 ± 1.59 ng/ml) and the lowest average IgG4 level could be found
in Group 1 (8.34 ± 0.58 ng/ml). On day-11, there was a greater difference of serum IgG4 level between all groups ($p = 0.005$). At day-10, the highest average IgG4 level could be found in Group 4 (LPS Pg 3 μg/ml; 63.74 ± 4.74 ng/ml) and the lowest average IgG4 level could be found in Group 1 (13.91 ± 0.99 ng/ml) (Table 3).

### Table 1. General characteristics of study population (n = 16; 4/group).

| Variable          | Group 1 (control) | Group 2 (LPS Pg 0.3 μg/ml) | Group 3 (LPS Pg 1 μg/ml) | Group 4 (LPS Pg 3 μg/ml) | p value |
|-------------------|-------------------|---------------------------|--------------------------|--------------------------|---------|
| Age (weeks)       | 8.87 ± 0.86       | 9.37 ± 0.95               | 8.75 ± 0.96              | 9.12 ± 0.63              | 0.774   |
| Weight (g)        | 135.25 ± 9.54     | 135.25 ± 9.55             | 137.25 ± 7.93            | 138.00 ± 10.98           | 0.700   |
| Male (%)          | 100               | 100                       | 100                      | 100                      | -       |
| IgE (pg/mL)       | 5.69 ± 0.28       | 5.36 ± 0.19               | 10.27 ± 0.70             | 6.69 ± 0.61              | 0.071   |
| IgG4 (ng/mL)      | 10.74 ± 1.41      | 11.76 ± 0.85              | 11.91 ± 1.66             | 10.14 ± 1.44             | 0.770   |
| IgG4/IgE ($\times 10^3$) | 1.87 ± 0.18 | 2.20 ± 0.13               | 1.19 ± 0.20              | 1.59 ± 0.34              | 0.053   |

*Data are presented as mean ± standard error of the mean (SEM).
**One-way ANOVA for categorical variables; significant at $p < 0.05$.
***IgE, immune globulin E; IgG4, immune globulin G4; IgG4/IgE, ratio between average IgG4 levels divided by average IgE levels.

#### Ratio of IgG4/IgE antibodies between the four groups
The average IgG4/IgE ratio for the control group at day-0, day-4, and day-11 was $1.87 \times 10^3$, $1.72 \times 10^3$, and $3.62 \times 10^3$, respectively. In Group 2 (low-dose LPS group; 0.3 μg/ml), the average IgG4/IgE ratio was $2.20 \times 10^3$, $1.27 \times 10^3$, and $0.22 \times 10^3$, respectively. In Group 3 (medium-dose LPS group; 1 μg/ml), the average IgG4/IgE ratio was $1.19 \times 10^3$, $0.69 \times 10^3$, and $0.56 \times 10^3$, respectively. In Group 4 (high-dose LPS group; 3 μg/ml), the average IgG4/IgE ratio was $1.59 \times 10^3$, $1.64 \times 10^3$, and $0.65 \times 10^3$, respectively. All groups exhibited significant differences of IgG4/IgE ratios, except at day-0. The highest IgG4/IgE ratio at day-4 and day-11 could be found in Group 1. The lowest IgG4/IgE ratio at day-4 could be found in Group 3, whilst the lowest ratio at day-11 could be found in Group 2 (Table 4).
Subgroup analysis

**Group 2 (0.3 μg/ml LPS Pg)**

Level of IgE were increased dramatically from day-0 to day-11 after experiments (5.36 ± 0.19 pg/ml to 180.34 ± 10.42 pg/ml; *p* = 0.011). Level of IgG4 also increases significantly from day-0 to day-11 after experiments (11.76 ± 0.85 ng/ml to 39.85 ± 2.14 ng/ml; *p* = 0.006). On the other hand, IgG4/IgE ratio were decreased following experiments (2.20 × 10³ to 0.22 ± 0.01 × 10³; *p* = 0.014) (Table 5).

**Group 3 (1 μg/ml LPS Pg)**

Level of IgE were raised dramatically from day-0 to day-11 after experiments (10.27 ± 0.70 pg/ml to 112.90 ± 3.87 pg/ml; *p* = 0.003). Level of IgG4 also increased significantly from day-0 to day-11 after experiments (11.91 ± 1.66 ng/ml to 63.6 ± 10.76 ng/ml; *p* = 0.027). On the other hand, IgG4/IgE ratio declined following experiments (1.19 ± 0.20 × 10³ to 0.56 ± 0.09 × 10³; *p* = 0.362) (Table 6).

---

**Table 2. Comparisons of total serum IgE (pg/mL) between the four groups (mean ± SEM).**

| Group               | n  | IgE day 0       | IgE day 4       | IgE day 11      |
|---------------------|----|----------------|----------------|----------------|
| Group 1 (control)   | 4  | 5.69 ± 0.28    | 5.31 ± 0.76    | 5.06 ± 1.86    |
| Group 2 (LPS Pg 0.3 μg/ml) | 4  | 5.36 ± 0.19    | 9.26 ± 0.32    | 180.34 ± 10.42 |
| Group 3 (LPS Pg 1 μg/ml) | 4  | 10.27 ± 0.70   | 17.00 ± 1.69   | 112.90 ± 3.87  |
| Group 4 (LPS Pg 3 μg/ml) | 4  | 6.69 ± 0.61    | 14.79 ± 0.86   | 102.01 ± 11.04 |
| F statistic         | /  | 20.733         | 26.171         | 83.758         |
| p value             | /  | 0.071          | 0.006          | 0.047          |

*Measured by one-way ANOVA (df1 = 3, df2 = 12, f table 3.490; significant at *p* < 0.05).
Table 3. Comparisons of total serum IgG4 (ng/mL) between the four groups (mean ± SEM).

| Group                        | n  | IgG4 day 0     | IgG4 day 4     | IgG4 day 11    |
|------------------------------|----|---------------|---------------|---------------|
| Group 1 (control)            | 4  | 10.74 ± 1.41  | 8.34 ± 0.58   | 13.91 ± 0.99  |
| Group 2 (LPS Pg 0.3 μg/ml)   | 4  | 11.76 ± 0.85  | 11.80 ± 0.83  | 39.85 ± 2.14  |
| Group 3 (LPS Pg 1 μg/ml)     | 4  | 11.91 ± 1.66  | 11.98 ± 1.65  | 63.6 ± 10.76  |
| Group 4 (LPS Pg 3 μg/ml)     | 4  | 10.14 ± 1.44  | 23.86 ± 1.59  | 63.74 ± 4.74  |

F statistic / 0.379 \( p \) value / 0.770

\( \text{p} \) value / 0.008

\( \text{p} \) value / 0.005

*Measured by one-way ANOVA (df1 = 3, df2 = 12, f table 3.490; significant at \( p < 0.05 \)).

Figure 3. Comparisons of IgG4/IgE ratio between four groups (mean ± SEM).

Table 4. Comparisons of IgG4/IgE ratio (x10^3) between the four groups (mean ± SEM)

| Group                        | n  | IgG4/IgE day 0     | IgG4/IgE day 4     | IgG4/IgE day 11    |
|------------------------------|----|-------------------|-------------------|-------------------|
| Group 1 (control)            | 4  | 1.87 ± 0.18       | 1.72 ± 0.36       | 3.62 ± 0.85       |
| Group 2 (LPS Pg 0.3 μg/ml)   | 4  | 2.20 ± 0.13       | 1.27 ± 0.08       | 0.22 ± 0.01       |
| Group 3 (LPS Pg 1 μg/ml)     | 4  | 1.19 ± 0.20       | 0.69 ± 0.03       | 0.56 ± 0.09       |
| Group 4 (LPS Pg 3 μg/ml)     | 4  | 1.59 ± 0.34       | 1.64 ± 0.20       | 0.65 ± 0.08       |

F statistic / 3.418 \( p \) value / 0.053

\( \text{p} \) value / 0.017

\( \text{p} \) value / <0.001

*Measured by one-way ANOVA (df1 = 3, df2 = 12, f table 3.490; significant at \( p < 0.05 \)).
Table 5. Comparisons of total serum IgE, IgG4, and IgG4/IgE ratio before and after treatment in Group 2 (exposure of 0.3 μg/mL LPS Pg) (mean ± SEM; n = 4).

| Time-point          | IgE (pg/mL) | IgG4 (ng/mL) | IgG4/IgE (x10⁻³) |
|---------------------|-------------|--------------|-------------------|
| Day-0 before treatment | 5.36 ± 0.19 | 11.76 ± 0.85 | 2.20 ± 0.13       |
| Day-4 after treatment | 9.26 ± 0.32 | 11.80 ± 0.83 | 1.27 ± 0.08       |
| Day-11 after treatment | 180.34 ± 10.42 | 39.85 ± 2.14 | 0.22 ± 0.01       |
| F statistic         | 93.924      | 178.233      | 71.969            |
| p value             | 0.011       | 0.006        | 0.014             |

*Measured by repeated measure ANOVA.
**df times = 2, df error = 14, f table 3.739; significant at p < 0.05.

Table 6. Comparisons of total serum IgE, IgG4, and IgG4/IgE ratio before and after treatment in Group 3 (exposure of 1 μg/mL LPS Pg) (mean ± SEM; n = 4).

| Time-point          | IgE (pg/mL) | IgG4 (ng/mL) | IgG4/IgE (x10⁻³) |
|---------------------|-------------|--------------|-------------------|
| Day-0 before treatment | 10.27 ± 0.70 | 11.91 ± 1.66 | 1.19 ± 0.20       |
| Day-4 after treatment | 17.00 ± 1.69 | 11.98 ± 1.65 | 0.69 ± 0.03       |
| Day-11 after treatment | 112.90 ± 3.87 | 63.6 ± 10.76 | 0.56 ± 0.09       |
| F statistic         | 294.526     | 35.437       | 1.760             |
| p value             | 0.003       | 0.027        | 0.362             |

*Measured by repeated measure ANOVA.
**df times = 2, df error = 14, f table 3.739; significant at p < 0.05.

Table 7. Comparisons of total serum IgE, IgG4, and IgG4/IgE ratio before and after treatment in Group 4 (exposure of 3 μg/mL LPS Pg) (mean ± SEM; n = 4).

| Time-point          | IgE (pg/mL) | IgG4 (ng/mL) | IgG4/IgE (x10⁻³) |
|---------------------|-------------|--------------|-------------------|
| Day-0 before treatment | 6.69 ± 0.61 | 10.14 ± 1.44 | 1.59 ± 0.34       |
| Day-4 after treatment | 14.79 ± 0.86 | 23.86 ± 1.59 | 1.64 ± 0.20       |
| Day-11 after treatment | 102.01 ± 11.04 | 63.74 ± 4.74 | 0.65 ± 0.08       |
| F statistic         | 111.386     | 32.929       | 7.841             |
| p value             | 0.009       | 0.029        | 0.113             |

*Measured by repeated measure ANOVA.
**df times = 2, df error = 14, f table 3.739; significant at p < 0.05.

Group 4 (3 μg/mL LPS Pg)

Level of IgE were raised dramatically from day-0 to day-11 after experiments (6.69 ± 0.61 pg/mL to 102.01 ± 11.04 pg/mL; p = 0.009). Level of IgG4 were also increase significantly from day-0 to day-11 after experiments (10.14 ± 1.44 ng/mL to 63.74 ± 4.74 ng/mL; p = 0.029). On the other hand, IgG4/IgE ratio declined following experiments (1.59 ± 0.34 × 10⁻³ to 0.65 ± 0.08 × 10⁻³; p = 0.113) (Table 7).

Discussion

Several mechanisms have been suggested to alter atopic inflammatory responses following LPS Pg infection. One of the mechanisms proven in this study is an elevation of IgE antibody and reduction of IgG4/IgE ratio. As far as we have known, Th-1 and Th-2 cells are not two different CD4+ T-cell subsets, but it represents polarized forms of the highly heterogenous CD4+ T-cell-mediated immune response. Host genetic and microenvironmental factors could have contributed with series of modulatory factors including: the ligation of T-cell receptor (TCR); the activation of costimulatory molecules and its particular components; the predominance of an inflammatory cytokine in the local environment; and the number of postactivation cell divisions following exposure to antigens. Down-regulation of the Th-1 cell is associated with depression
of cell-mediated immune response and stimulation of humoral immune response, thus pathogens are able to evade immune clearance.25

*Porphyromonas gingivalis* possess very sophisticated defense mechanisms against host immune responses. These pathogens produce capsules containing long chain LPS which is designed effectively to counter membrane attack complex. These long chain LPS can also downgrade cell-mediated immunity by shifting Th-1 into Th-2 which less dangerous to pathogens.26 LPS may have an essential role in switching cell-mediated to humoral-mediated immune responses.27 LPS Pg antigen is processed and presented on its surface with MHC-II molecule. Recent studies suggest an activation of alternative complement pathway, disruption of classical complement pathway, modulation of antigen presenting cells, and downregulation of anti-inflammatory cytokines are responsible for the Th2-skewed immune response following exposure to LPS Pg. Predominance shifting from Th-1 into Th-2 occurs in several extra-lymphoid tissues; the ideal site for *Porphyromonas gingivalis* is the oral cavity.28

Interleukin-4 (IL-4), which is produced by naive T cells, acts as autocrine manner known to be responsible for the differentiation and activation of Th-2 phenotype.29 Guo et al (2014) shows upon the occurrence and development of allergic diseases, there is a complex pathobiology which results in an imbalance of Th-1/Th-2.30 In an atopic disease such as bronchial asthma or urticaria, naive T cell can differentiate into Th-2 under IL-4–induced STAT6 and GATA-3 transcription factors.30 Th-2 predominant immune response will automatically stimulate plasma cell to release IgE and IgG4.31 Upon re-exposure of antigen or allergen, binding of the allergen to IgE orchestrates the adaptive immune system to initiate rapid sensitization. Frequent sensitization is a major risk factor for the development of allergic diseases such as urticaria, bronchial asthma, hay fever or atopic dermatitis/eczema.32

Our previous study used whole-cell body of *Porphyromonas gingivalis* to study different molecular responses in Wistar rats. Our first project studied the association between periodontal pathogen and host innate immunity. Exposure to *Porphyromonas gingivalis* had been shown to stimulate level of TLR2 and depress level of TLR4.33 Our findings might indicate that several bacterial properties can turn-off host innate immunity and host inflammatory response. Our second project studied the association between periodontal pathogen and host adaptive immunity. We summarized that high dose CFU of Pg stimulates fold increase of Th-2 cytokines (IL-4, IL-5 and IL-13) and decrease of Th-1 cytokines (IFN-γ and IL-17).34 These were the cornerstone to continue our project in studying LPS as the most important component of these bacteria.

At this moment, both total IgE or specific IgE antibodies have little diagnostic value in the occurrence of allergic manifestation. Even total or specific IgE is increasing, yet the manifestation of allergy doesn’t usually develop, since IgG4 level also increases as a counter-regulator.35 It means that even human or rat become susceptible to atopic allergy due to the increasing level of IgE, body mechanism is able to provide protection, with increased IgG4 as a counter response to prevent manifestation of allergic diseases and immediate hypersensitivity. Thus, exposure of LPS Pg will develop chance of atopic and hypersensitivity markers, but manifestation of allergic reaction is a complex pattern.36 IgG4/IgE ratio has closer accuracy to detect any alteration of atopic inflammatory pathway. Increase level of IgE, which isn’t accompanied by IgG4, can be seen in patients with urticaria or atopic dermatitis.37 IgE-switched B cells are much more likely to differentiate into plasma cells, whereas IgG4-switched B cells are less likely to differentiate.38 This reason would explain why IgE antibody is the most dominant antibody in the development of atopic inflammatory pathway, whereas IgG4 antibodies become prominent later during chronic non-atopic stimulation.39 According to this reason, IgG4/IgE ratio may predict atopic responses more accurately than total or specific IgE level.

**Limitations and strengths**

Several limitations should be highlighted. First, this study had limitations with regard to very small number of samples which can increase the likelihood of error and imprecision. Second, results from animal models often do not translate into replications in humans.40 IgE antibody responses in Wistar rats are typically transient, whereas the atopic IgE response in human persists for many years.31 Other crucial difference is IgG4/IgE ratio, which is usually much higher in the Wistar rats than humans.42–43 These factors may have an impact on the interpretation of our results. Thus, the findings should be interpreted within the context of this study and its limitations. The strengths of the study were its high statistical power and the homogeneity of each group to enable comparison between groups and periods.

**Conclusion**

Several experiments in rats indicate that exposure to LPS Pg may have a tendency to increase levels of IgE and IgG4. On the contrary, declining IgG4/IgE ratio following exposure to LPS Pg suggests the potential role of LPS Pg for isotype switching from IgG4 to IgE. The results of the present study favor indirect isotype switching route for most IgE as secondary responses from LPS Pg infection that leads to systemic atopic inflammatory pathway.
Data availability
Underlying data

Figsshare: Raw Data - Atopic Biomarker Changes after Exposure to Porphyromonas gingivalis Lipopolysaccharide: A Small Experimental Study in Wistar Rat, https://doi.org/10.6084/m9.figsshare.14350271.v1.44

This project contains the following underlying data:

- Data fixed LPS grup A.sav (Group 1 results)
- Data fixed LPS grup B1.sav (Group 2 results)
- Data fixed LPS grup B2.sav (Group 3 results)
- Data fixed LPS grup B3.sav (Group 4 results)

Data are available under the terms of the Creative Commons Attribution 4.0 International license (CC-BY 4.0).

Acknowledgments

This project is fully supported by Agung Sosiawan as Dean of Universitas Airlangga College of Dentistry and Coen Pramono as Director of Airlangga Oral and Dental Hospital. We would like to acknowledge Harjanto from Physiology Department and Indrawati Retno from Biochemistry Department for providing material and reagent generation. We also thank all lecturers and research assistants from Universitas Airlangga, who are willing to help in the technical aspect.

A previous version of this article is available on bioRXiv: https://doi.org/10.1101/2021.01.14.426656.

References

1. Herrero ER, Fernandes S, Verspecht T, et al.: Dysbiotic Biofilms Deregulate the Periodontal Inflammatory Response. J Dent Res. 2019; 98(5): 547-553. PubMed Abstract | Publisher Full Text
2. Mazurek-Mochol M, Majorczyk E, Banach J, et al.: The influence of KIR gene presence/absence polymorphisms on the development of periodontal disease in smokers and non-smokers. Cent Eur J Immunol. 2017; 42(4): 347–53. PubMed Abstract | Publisher Full Text | Free Full Text
3. Sperr M, Kundi M, Tursic V, et al.: Prevalence of Comorbidities in Periodontitis Patients Compared to the General Austrian Population. J Periodontol. 2018; 89(1): 19–27. PubMed Abstract | Publisher Full Text
4. Taranun F, Faizuddin M: Effect of gene polymorphisms on periodontal diseases. Indian. J Hum Genet. 2012; 18(1): 9-19. PubMed Abstract | Publisher Full Text | Free Full Text
5. Pathan MM, Bhat KG, Joshi VM: Comparative evaluation of the efficacy of a herbal mouthwash and chlorhexidine mouthwash on select periodontal pathogens: An in vitro and ex vivo study. J Indian Soc Periodontol. 2017; 21(4): 270-275. PubMed Abstract | Publisher Full Text | Free Full Text
6. Pippin RA, Kizziar RJ, Sayehmiri F, et al.: Study of Porphyromonas gingivalis in periodontal diseases: A systematic review and meta-analysis. Med J Islam Repub Iran. 2017; 31: 62. PubMed Abstract | Publisher Full Text | Free Full Text
7. Rafei M, Kiani F, Sayehmiri F, et al.: Relationship between expression of human gingival beta-defensins and levels of periodontopathic genes in subgingival plaque. J Periodontal. 2014; 50(1): 113-122. PubMed Abstract | Publisher Full Text
8. Tomita S, Komiya-Ito A, Inamura K, et al.: Prevalence of Aggregatibacter actinomycetemcomitans, Porphyromonas gingivalis and Tannerella forsythia in Japanese patients with generalized chronic and aggressive periodontitis. Microb Pathog. 2013; 51(1): 40-47. PubMed Abstract | Publisher Full Text
9. Ting Z, Hong X, Zhaohui Y: Relationships of five periodontal pathogens causing subgingival plaque in patients with chronic periodontitis under different periodontal conditions. West Chin J Stomatol. 2013; 5: 518–21. PubMed Abstract
10. Wang P, Duan D, Zhou X, et al.: Relationship between expression of human gingival beta-defensins and levels of periodontopathogens in subgingival plaque. J Periodontal. 2014; 95(1): 98-106. PubMed Abstract | Publisher Full Text | Free Full Text
11. Amano A, Kubonishi A, Nakagawa I, et al.: Prevalence of specific genotypes of Porphyromonas gingivalis fimA and periodontal health status. J Dent Res. 2000; 79(9): 1664-8. PubMed Abstract | Publisher Full Text
12. Lu R, Feng L, Gao X, et al.: Relationship between volatile fatty acids and Porphyromonas gingivalis and Treponema denticola in gingival crevicular fluids of patients with aggressive periodontitis. Beijing Da Xue Xue Bao. 2013; 45(1): 12-16. PubMed Abstract
13. Finotti A, Girardi A, Palmieri A, et al.: Microflora and periodontal disease. Dent Res J (Istanbul). 2012; 92(3): 5202-6. PubMed Abstract | Publisher Full Text | Free Full Text
14. Carinci F, Scapoli L, Girardi A, et al.: Oral microflora and periodontal disease: new technology for diagnosis in dentistry. Ann Stomatol. 2013; 5(2): 170-3. PubMed Abstract | Free Full Text
15. Avila-Campos MJ, Velasquez-Melendez G: Prevalence of putative periodontopathogens from periodontal patients and healthy subjects in São Paulo SP Brazil. Rev Inst Med trop S Paulo. 2002; 44(1): 1-5. PubMed Abstract | Publisher Full Text
18. Wilson M, Logatin D, Osborne G, et al.; Prevalence of Treponema denticola and Porphyromonas gingivalis in plaque from periodontally-healthy and periodontally-diseased sites. J Med Microbiol. 1993; 38: 406-10. PubMed Abstract | Publisher Full Text

19. Riep B, Edesi-Neuss L, Claessen F, et al.; Are putative periodontal pathogens reliable diagnostic markers? J Clin Microbiol. 2009; 47(5): 1705-11. PubMed Abstract | Publisher Full Text | Free Full Text

20. Kato A, Imai K, Ochiai K, et al.; Higher Prevalence of Epstein-Barr Virus DNA in Deeper Periodontal Pockets of Chronic Periodontitis in Japanese Patients. PLoS ONE. 2013; 8(8): e71990. PubMed Abstract | Publisher Full Text | Free Full Text

21. Kato A, Imai K, Ochiai K, et al.; Salivary detection of periodontopathic bacteria in Fanconi’s anemia patients. Anorebro. 2013; 24: 52-55. PubMed Abstract | Publisher Full Text

22. Raffel M, Kiani F, Sayehmiri F, et al.; Study of Porphyromonas gingivalis in periodontal diseases: A systematic review and meta-analysis. Med J Islam Repub Iran. 2017; 31: 62. PubMed Abstract | Publisher Full Text | Free Full Text

23. Okamoto S, Tanichi S, Sudoh K, et al.; Predictive value of IgE/IgG4 antibody ratio in children with egg allergy. Asthma Allergy Clin Immunol. 2012; 8: 9. PubMed Abstract | Publisher Full Text | Free Full Text

24. Portnoy J; IgE in Clinical Allergy and Allergy Diagnosis. [accessed on 1 July 2018]. Reference Source

25. Herman RA, Ladics GS; Allergic sensitization versus elicitation risk criteria for novel food proteins - short communication. Regul Toxicol Pharmacol. 2018; 93: 185-8. PubMed Abstract | Publisher Full Text

26. Matthews CR, Joshi V, de Jager M, et al.; Allergenic sensitization versus elicitation risk criteria for novel food proteins - short communication. Regul Toxicol Pharmacol. 2018; 93: 185-8. PubMed Abstract | Publisher Full Text

27. Finlay BB, McFadden G; Anti-ImmunoLOGY: Evasion of the Host Immune System by Bacterial and Viral Pathogens. Cell. 2006; 124(4): 767-782. PubMed Abstract | Publisher Full Text

28. Schmid-Hempel P; Immune defence, parasite evasion strategies and their relevance for ‘macroscopic phenomena’ such as virulence. Philos Trans R Soc Lond B Biol Sci. 2009; 364(1513): 85-98. PubMed Abstract | Publisher Full Text | Free Full Text

29. Theodorou GL, Maroulis S, Ellul J, et al.; T helper 1 (Th1)/Th2 cytokine expression shift of peripheral blood CD4+ and CD8+ T cells in patients at the post-acute phase of stroke. Clin Exp Immunol. 2008; 152(3): 456-63. PubMed Abstract | Publisher Full Text | Free Full Text

30. Guo HW, Yum CX, Hou GH, et al.; Mangiferin attenuates TH1/TH2 cytokine imbalance in an ovalbumin-induced asthmatic mouse model. PLoS One. 2014; 9: e100394. PubMed Abstract | Publisher Full Text | Free Full Text

31. Ettinger R, Karmeli J, Haenut J, et al.; Pathogenic mechanisms of IgE-mediated inflammation in self-destructive autoimmune responses. Autoimmunity. 2017; 50(1): 25-36. PubMed Abstract | Publisher Full Text

32. Varricchi G, Raap U, Rivellese F, et al.; Human mast cells and basophils-How are they similar how are they different? Immuno Rev. 2018; 282(1): 8-34. PubMed Abstract | Publisher Full Text

33. Nelwan SC, Nugraha RA, Endaryanto A, et al.; Modulating toll-like receptor-mediated inflammatory responses following exposure of whole cell and lipopolysaccharide component from Porphyromonas gingivalis in wistar rat models. Eur J Dent. 2017; 11(4): 422-6. PubMed Abstract | Publisher Full Text | Free Full Text

34. Nelwan SC, Nugraha RA, Endaryanto A, et al.; Converging findings from linkage between periodontal pathogen with atopic and allergic immune response. Cytokine. 2019; 113: 89-98. PubMed Abstract | Publisher Full Text

35. Saulite I, Hoetzerencker W, Guenova E, et al.; Skin Test Reactivity to Hymenoptera Venom after Venom Immunotherapy Correlates Inversely with the IgG/IgG4 Ratio. Int Arch Allergy Immunol. 2017; 174(5-6): 190-9. PubMed Abstract | Publisher Full Text

36. Garman L, Smith K, Muns EE, et al.; Unique Inflammatory Mediators and Specific IgE Levels Distinguish Local from Systemic Reactions after Anthrax Vaccine Adsorbed Vaccination. Clin Vaccine Immunol. 2016; 23(8): 664-71. PubMed Abstract | Publisher Full Text | Free Full Text

37. Deo SS, Mistry KJ, Kakade AM, et al.; Role played by Th2 type cytokines in IgE mediated allergy and asthma. Lung India. 2010; 27(2): 66-71. PubMed Abstract | Publisher Full Text | Free Full Text

38. Kubo M; T follicular helper and TH2 cells in allergic responses. Allergol Int. 2017; 66(3): 377-81. PubMed Abstract | Publisher Full Text

39. Zhang Y, Fear DJ, Willis-Owen SA, et al.; Global gene regulation during activation of immunoglobulin class switching in human B cells. Sci Rep. 2016; 6: 3798. PubMed Abstract | Publisher Full Text | Free Full Text

40. Platts-Mills TA, Vaughan JW, Blumenthal K, et al.; Serum IgG and IgG4 antibodies to Fel d 1 among children exposed to 20 microg Fel d 1 at home: relevance of a nonallergic modified Th2 response. Int Arch Allergy Immunol. 2001; 124: 126-9. PubMed Abstract | Publisher Full Text | Free Full Text

41. Ramadani F, Bowen H, Upton N, et al.; Ontogeny of human IgE-expressing B cells and plasma cells. Allergy. 2017; 72(1): 66-76. PubMed Abstract | Publisher Full Text | Free Full Text

42. Aalberse RC, Platts-Mills TA, Rispens T; The Developmental History of IgE and IgG. Antibodies in Relation to Atopy. Eosinophilic Esophagitis, and the Modified Th2 Response. Curr Allergy Asthma Rep. 2016; 16(6): 45. PubMed Abstract | Publisher Full Text | Free Full Text

43. Hatipoğlu U, Subramanian A, Campbell T, et al.; Intrasubject Variability in Total IgE Levels in Patients with Moderate to Severe Persistent Allergic Asthma Over 1 Year. J Allergy Clin Immunol Pract. 2016; 4(6): 691-6. PubMed Abstract | Publisher Full Text

44. Nelwan SC, Nugraha RA, Endaryanto A, et al.; Raw Data - Atopic Biomarker Changes after Exposure to Porphyromonas gingivalis Lipopolysaccharide: A Small Experimental Study in Wistar Rat. figshare. Dataset. 2021. Publisher Full Text

Abbreviations

ANOVA analysis of variant

BCR B cell receptor

CD-40 Cluster Differentiation-40

CFU colony-forming unit

CSR class-switch recombination
df degree of freedom

ELISA enzyme-linked immunosorbent assay

FDA Food and Drug Administration

HDM house dust mite

IAUCU Institutional Animal Care and Use Committee

IFN-γ gamma-Interferon

IgE immunoglobulin-E

IgG4 immunoglobulin-G4
IL interleukin
LLPC long-lived plasma cell
LPS lipopolysaccharide
mAb monoclonal antibody
MAC membrane attack complex
MHC major histocompatibility complex
NIH National Institutes of Health
NGS next-generation sequencing
NK natural killer cells
OIT oral immunotherapy
PAMP pathogen-associated molecular patterns
PCR Polymerase Chain Reaction
Pg Porphyromonas gingivalis
SD standard deviation
SEM standard error of the mean
SPSS Statistical Package for the Social Sciences
Th-1 type-1 helper T-cells
Th-2 type-2 helper T-cells
TNF-α Tumor Necrosis Factor-α
The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com